# 乙型肝炎疫苗市场

> 乙型肝炎疫苗市场研究报告按类型（单价疫苗、组合疫苗）、按分销渠道（医院药房、零售药房、诊所、在线门户）、按年龄组（儿童、成人、老年人）及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测至2035年

- **Forecast Period:** 2026-2035
- **CAGR:** 6.65%
- **2025:** USD 9.05 Billion
- **2035:** USD 17.20 Billion
- **Key Players:** GlaxoSmithKline, Merck & Co., Serum Institute of India, Sanofi, Dynavax Technologies, Bharat Biotech, Sinovac Biotech, Panacea Biotec

**Report ID:** MRFR/Pharma/27698-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** July 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/hepatitis-b-vaccine-market-29415

---

## Market Summary

 

## Hepatitis B Vaccine Market Summary

The hepatitis B vaccine Market reached USD 9.05 billion in 2025, with the 2026 forecast opening near USD 9.65 billion and tracking toward USD 17.20 billion by 2035 at a 6.65% CAGR. Two catalysts anchor this trajectory. First, government-led birth-dose mandates continue to widen the addressable base — India's Universal Immunization Programme alone delivers free coverage against twelve diseases, hepatitis B included, and helped cut the under-5 mortality rate from 45 to 32 per 1,000 live births between 2014 and 2020. Second, sustained Gavi co-financing has pulled lower-income economies into routine procurement cycles, smoothing demand volatility that once made the hepatitis B vaccine Market difficult to forecast.

Technology is reshaping how doses reach patients. Legacy multi-dose vials drawn with conventional needles are giving way to prefilled syringes and needle-free delivery — in May 2024, the Serum Institute of India took a 20% stake in IntegriMedical to scale Needle-Free Injection System technology. Recombinant hepatitis B shot platforms have largely displaced plasma-derived antigen production, improving safety and yield. Neonatal HBV vaccination programs increasingly favor combination formulations that bundle the antigen with DTP and Hib components, reducing cold-chain trips.

North America holds the dominant position with roughly 33% of global revenue, anchored by mature reimbursement and adult catch-up programs. Asia-Pacific is the fastest-growing region at a 7.4% CAGR, propelled by birth-dose scale-up across China, India, and ASEAN. Europe ranks second, supported by harmonized EU immunization guidance. The decade ahead favors integrated liver disease prevention vaccine strategies over single-disease campaigns.

### Section 2 — Key Report Takeaways

### By Vaccine Type

- Recombinant single-antigen formulations command approximately 58% revenue share, reflecting decades of installed manufacturing capacity
- Combination vaccines are the fastest-growing technology class at a 7.8% CAGR as neonatal HBV vaccination shifts toward multi-antigen schedules

### By Age Group

- Pediatric immunization accounts for roughly USD 5.6 billion of 2025 demand within the hepatitis B vaccine Market, driven by birth-dose mandates
- Adult catch-up vaccination is expanding at a 6.9% CAGR as occupational and high-risk screening widens

### By Region

- North America leads with about 33% of global revenue
- Asia-Pacific posts the strongest regional CAGR at 7.4%, the key growth engine for the hepatitis B vaccine Market
- Europe contributes an estimated USD 2.3 billion in 2025

## Section 3 — Market Size and Forecast (2021–2035)

MRFR sizes the hepatitis B vaccine Market by triangulating procurement disclosures from UNICEF Supply Division, Gavi co-financing records, manufacturer annual reports, and national immunization budgets, cross-checked against WHO coverage estimates. The 2024–2025 step reflects post-pandemic catch-up campaigns that compressed deferred birth doses into a single reporting window.

 

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Government birth-dose mandates | 24% | Global | Long-term |   |
| Rising HBV prevalence awareness | 17% | Asia-Pacific, MEA | Medium-term |   |
| Gavi co-financing expansion | 16% | Low-income economies | Long-term |   |
| Needle-free delivery innovation | 13% | North America, Asia | Medium-term |   |
| Combination vaccine adoption | 12% | Global | Medium-term |   |
| Adult high-risk screening programs | 10% | North America, Europe | Short-term |   |
| Local manufacturing investment | 8% | MEA, South America | Long-term |   |

### Government Birth-Dose Mandates

National schedules increasingly require a hepatitis B dose within 24 hours of birth, the single most effective intervention against perinatal transmission. The WHO South-East Asia Region reported birth-dose coverage rising past 60% in 2024, with India's UIP delivering free hepatitis B immunization as part of a twelve-disease schedule. Each percentage point of birth-dose coverage gain translates into measurable procurement volume, and the HBV immunization schedule embedded in routine [pediatric care](https://www.marketresearchfuture.com/reports/pediatric-healthcare-market-2778) makes this driver structurally durable.

### Gavi Co-Financing Expansion

With nearly USD 1.6 billion in vaccination support distributed across hepatitis-inclusive initiatives in recent cycles, Gavi's co-financing strategy commits low-income economies to graded cost-sharing. In particular, for pentavalent formulations including the HBV antigen, this transforms sporadic donor financing into steady multi-year demand. Access to liver disease prevention vaccines in markets that would not otherwise be able to support procurement is supported by this approach.

### Needle-Free Delivery Innovation

In areas where coverage is limited by needle phobia and sharps disposal logistics, investment in delivery technologies is accelerating uptake. In May 2024, the Serum Institute of India announced a 20% USD ownership in IntegriMedical, indicating the manufacturer's belief that needle-free methods will increase the reach of both adult catch-up programs and neonatal HBV vaccination. The overall program economics are improved by a decreased cold-chain and disposal burden.

 

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Price erosion from tendered procurement | 28% | Global | Long-term |   |
| Vaccine hesitancy pockets | 21% | North America, Europe | Medium-term |   |
| Cold-chain gaps in remote regions | 19% | MEA, South America | Medium-term |   |
| Mature-market coverage saturation | 18% | North America, Europe | Long-term |   |
| Manufacturing concentration risk | 14% | Global | Short-term |   |

### Price Erosion from Tendered Procurement

Pooled procurement through UNICEF and PAHO revolving funds drives per-dose prices down to a few cents in low-income tiers. While this expands access, it compresses manufacturer margins and caps revenue growth even as volumes climb. UNICEF Supply Division weighted average hepatitis B prices have stayed under USD 0.30 per dose in recent tenders, a structural ceiling on value capture for the hepatitis B vaccine Market.

### Vaccine Hesitancy Pockets

In some regions of North America and Europe, localized hesitation hampers adult catch-up acceptance despite the recombinant hepatitis B vaccine's excellent safety records. Hepatitis B series completion is well below the Healthy People 2030 objective, according to CDC adult coverage data, indicating unmet demand. Hesitancy is a medium-term rather than a permanent drag since it is concentrated rather than general.

### Cold-Chain Gaps in Remote Regions

WHO predicts that last-mile cold-chain failures in portions of sub-Saharan Africa and the Amazon basin result in waste rates that can surpass 10% in challenging regions. Hepatitis B antigen-based vaccine necessitates persistent storage at 2–8°C. Emerging solutions include freeze-tolerant formulations and controlled-temperature-chain trials, but infrastructure is still the limiting factor.

 

## Hepatitis B Vaccine Market Opportunities

### Emerging-Market Birth-Dose Scale-Up

The widest growth runway sits in low- and middle-income economies where birth-dose coverage still trails routine third-dose coverage. Closing that timeliness gap across the WHO African Region alone would add several hundred million doses of cumulative demand through 2035, tying directly to the prevalence drivers in

### Combination Vaccine Bundling

Pentavalent and hexavalent formulations that fold the HBV antigen into a single injection reduce visits and cold-chain trips. As neonatal HBV vaccination consolidates around combination products, manufacturers able to supply WHO-prequalified hexavalent doses capture a disproportionate share — a trend quantified in

### Needle-Free and Self-Administration Platforms

Needle-free injection and microarray patch development open self-administration use cases for adult catch-up. These platforms lower the skilled-staff requirement and could unlock pharmacy-channel growth, building on the delivery innovation discussed in

### Localized Manufacturing in Underserved Regions

Donor-backed initiatives to establish vaccine plants in Africa create both supply security and procurement-preference opportunities. Manufacturers co-locating fill-finish capacity near demand benefit from tender scoring that rewards regional sourcing.

### Data-Driven Coverage Analytics as a Service

Digital immunization registries generate granular coverage data that manufacturers and ministries can monetize through demand-forecasting and defaulter-tracking services — a new business model layered on top of the core liver disease prevention vaccine franchise.

 

## Hepatitis B Vaccine Market Future Outlook

### Digital Immunization Intelligence

Electronic immunization registries will become the operating system of vaccine delivery. WHO targets near-universal digital registry adoption across member states by the early 2030s, enabling defaulter tracking that lifts birth-dose timeliness — the metric most correlated with hepatitis B vaccine Market growth.

### Delivery Platform Economics

Needle-free injectors and microarray patches will reframe cost structures. As per-device costs fall with scale, the addressable channel widens from clinics to pharmacies and community health workers, extending the recombinant hepatitis B shot beyond traditional settings.

### Elimination-Driven Demand

WHO's 2030 viral hepatitis elimination targets — a 90% reduction in new infections — require sustained high birth-dose coverage. Countries pursuing certification will lock in procurement budgets, converting an aspirational goal into contracted demand for hepatitis antigen-based immunization.

### Regional Manufacturing Sovereignty

The drive for African vaccine self-sufficiency, backed by the Africa CDC goal of producing 60% of the continent's vaccines locally by 2040, will reshape supply geography. Localized fill-finish capacity reduces import dependence and reshapes tender dynamics for the hepatitis B vaccine Market.

 

## Regional Market Share Analysis

| Region | Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 33% share | Adult catch-up, reimbursement depth |
| Europe | USD 2.30 B | Harmonized EU schedules |
| Asia-Pacific | 7.4% CAGR | Birth-dose scale-up |
| South America | USD 0.78 B | PAHO revolving fund procurement |
| Middle East & Africa | 8.1% CAGR | Local manufacturing, donor programs |
| Total | USD 9.05 B (2025) | — |

Regional shares below sum to the global total; each row discloses a single metric for clarity. The hepatitis B vaccine Market remains North America-led, but Asia-Pacific is closing the gap fastest.

### North America

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| US | 84% | Adult high-risk vaccination guidance |
| Canada | 11% | Provincial school-entry programs |
| Mexico | 5% | Universal infant immunization |

North America's leadership rests on reimbursement breadth and the 2022 CDC recommendation extending hepatitis B vaccination to all adults aged 19–59. That single policy shift converted a pediatric-dominated market into one with a structural adult tail, supporting premium-priced recombinant hepatitis B shot demand that pooled-procurement regions cannot match.

### Europe

| Country | USD Million (2025) | Key Driver |
| --- | --- | --- |
| Germany | 540 | STIKO universal infant schedule |
| UK | 430 | Selective neonatal program |
| France | 390 | Mandatory infant vaccination |
| Italy | 320 | Long-standing universal mandate |
| Spain | 250 | Regional immunization budgets |
| Nordic Countries | 180 | Risk-based targeting |
| Russia | 120 | National calendar inclusion |
| Rest of Europe | 70 | Mixed schedules |

Europe's market reflects divergent national strategies — France and Italy run universal mandatory infant vaccination, while the UK historically used selective neonatal targeting before broadening coverage. Harmonization pressure from ECDC guidance is gradually narrowing these differences, lifting baseline demand.

### Asia-Pacific

| Country | CAGR (2026–2035) | Key Driver |
| --- | --- | --- |
| China | 6.9% | Universal birth-dose program |
| India | 8.3% | UIP expansion |
| Japan | 4.8% | Mature universal coverage |
| South Korea | 5.1% | National immunization registry |
| ASEAN | 8.6% | Donor-backed scale-up |
| Rest of Asia-Pacific | 7.9% | Coverage gap closure |

Asia-Pacific is the engine of the hepatitis B vaccine Market. China's universal birth-dose program, sustained since the 1990s, now exceeds 95% timely coverage, while India's UIP continues expanding HBV immunization schedule reach into underserved districts. ASEAN economies show the steepest growth as Gavi transition and donor support converge.

### South America

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| Brazil | 62% | National immunization program |
| Argentina | 21% | Universal infant mandate |
| Rest of South America | 17% | PAHO revolving fund access |

South America's procurement runs largely through the PAHO Revolving Fund, which pools demand to secure competitive pricing. Brazil dominates regional volume, and its long-standing universal hepatitis antigen-based immunization policy provides a stable demand floor that smooths regional forecasts.

### Middle East & Africa

| Country | USD Million (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 145 | Mandatory infant and adult programs |
| UAE | 95 | Comprehensive immunization mandate |
| South Africa | 130 | EPI birth-dose rollout |
| Egypt | 110 | National hepatitis elimination plan |
| Rest of MEA | 290 | Gavi-supported routine programs |

The Middle East & Africa carries the widest coverage gap and therefore the steepest opportunity. Egypt's national hepatitis elimination plan, which integrated birth-dose vaccination with mass screening, demonstrates how the liver disease prevention vaccine fits into a broader elimination strategy. Gavi-supported routine programs underpin sub-Saharan demand.

 

## Hepatitis B Vaccine Market Segmentation

### By Vaccine Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Single Antigen Vaccine | 58% share | Birth-dose monovalent administration |
| Combination Vaccine | 7.8% CAGR | Pentavalent/hexavalent bundling |

Single-antigen vaccines dominate the hepatitis B vaccine Market because the monovalent birth dose must be given before combination schedules begin. Combination vaccines, however, capture the faster growth — pentavalent and hexavalent formulations consolidate the HBV immunization schedule into fewer injections, and WHO prequalification of hexavalent products is accelerating the shift across routine pediatric programs.

### By Age Group

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Pediatric | USD 5.62 B | Birth-dose and infant series mandates |
| Adult | 6.9% CAGR | High-risk and occupational catch-up |

Pediatric demand anchors the market through universal birth-dose and infant-series mandates that make neonatal HBV vaccination near-compulsory in most national calendars. Adult demand grows faster on the back of expanded recommendations covering healthcare workers, dialysis patients, and the 2022 US universal adult guidance.

### By Packaging Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Vials | 49% share | Cost-efficient multi-dose programs |
| Prefilled Syringes | 8.4% CAGR | Dosing accuracy, reduced wastage |
| Ampoules | USD 1.05 B | Legacy procurement contracts |

Vials retain share through multi-dose cost efficiency in high-volume programs, but prefilled syringes grow fastest as ministries prioritize dosing accuracy and lower open-vial wastage. Ampoules persist mainly in legacy contracts.

### By Distribution Channel

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Government Organizations | 54% share | National immunization procurement |
| Hospitals | USD 2.45 B | Birth-dose administration point |
| Non-Government Organizations | 7.2% CAGR | Donor-funded outreach |
| Others | 6% share | Pharmacy and travel clinics |

Government organizations dominate distribution as the primary procurers of routine immunization supply, channeling pooled tenders. Hospitals matter as the physical point of birth-dose administration, while NGOs grow fastest by extending reach into populations outside formal health systems.

 

## Competitive Benchmarking

The hepatitis B vaccine Market is moderately concentrated, with an estimated HHI in the 1,400–1,800 range and the top five suppliers holding roughly 62–68% of global revenue. Concentration is highest in high-income segments where regulatory and manufacturing barriers are steep; the pooled-procurement tier is more fragmented as regional producers compete on price.

| Company | Est. Revenue Share Range | Key Offerings for the Hepatitis B Vaccine Market | Strategic Positioning |
| --- | --- | --- | --- |
| GlaxoSmithKline | ~18–22% | Engerix-B, combination pediatric vaccines | Premium recombinant leader |
| Merck & Co. | ~15–19% | Recombivax HB, adult formulations | Strong North America franchise |
| Serum Institute of India | ~12–16% | Pentavalent, monovalent HBV | High-volume low-cost supply |
| Sanofi | ~8–11% | Hexavalent combination vaccines | Combination-vaccine specialist |
| Dynavax Technologies | ~6–9% | Heplisav-B adjuvanted two-dose | Adult innovation positioning |
| Bharat Biotech | ~5–8% | Revac-B recombinant vaccine | Emerging-market focus |
| Sinovac Biotech | ~4–7% | Recombinant HBV vaccine | China and export markets |
| Panacea Biotec | ~3–6% | Pentavalent and HBV vaccines | Tender-driven supply |
| LG Chem | ~3–5% | Euvax B recombinant vaccine | Asia-Pacific distribution |
| Biological E. Limited | ~2–4% | Combination pediatric vaccines | Gavi-aligned volume producer |

 

## Recent News & Developments

- [Serum Institute](https://www.seruminstitute.com/product_ind_genevacb.php) of India (May 2024): Acquired a 20% stake in IntegriMedical to advance Needle-Free Injection System technology, signaling delivery-platform diversification.
- Dynavax Technologies (March 2024): Reported expanded Heplisav-B adult uptake in US retail pharmacy channels, reinforcing the two-dose adult catch-up case.
- Government of India (November 2024): Highlighted UIP success in cutting under-5 mortality, with hepatitis B among twelve diseases covered free of charge.
- WHO (April 2024): Updated position paper reaffirming the universal timely birth dose as the priority intervention against perinatal HBV transmission.
- Gavi (December 2023): Confirmed continued co-financing support to strengthen lower-income economies' immunization readiness post-pandemic.
- [Bharat Biotech](https://www.bharatbiotech.com/revacb_mcf.html) (September 2023): Expanded Revac-B production capacity to serve rising pentavalent demand across African tenders.
- Sanofi (June 2024): Secured additional WHO prequalification volumes for its hexavalent combination vaccine, accelerating combination adoption.
- Egypt Ministry of Health (February 2024): Integrated birth-dose vaccination into its national hepatitis elimination program, linking immunization with mass screening.

### Section 12 — Report Scope and Methodology

### Section 13 — Detailed Sources and Citations

| # | Full Citation | URL / Source |
| --- | --- | --- |
| 1 | WHO & UNICEF, Immunization Coverage Estimates, 2024 | who.int |
| 2 | UNICEF Supply Division, Vaccine Price Data, 2024 | unicef.org/supply |
| 3 | Gavi, Annual Progress Report, 2023 | gavi.org |
| 4 | WHO, Global Hepatitis Report, 2024 | who.int |
| 5 | Market Research Future, Hepatitis B Vaccine Market Model, 2025 | marketresearchfuture.com |
| 6 | Government of India, UIP Performance Brief, 2024 | mohfw.gov.in |
| 7 | WHO, Hepatitis B Vaccine Position Paper, 2024 | who.int |
| 8 | Gavi, Co-Financing Policy Update, 2023 | gavi.org |
| 9 | Serum Institute of India, Press Release, May 2024 | seruminstitute.com |
| 10 | Sanofi, Annual Report, 2024 | sanofi.com |
| 11 | Dynavax Technologies, Investor Presentation, 2024 | dynavax.com |
| 12 | Bharat Biotech, Capacity Expansion Announcement, 2023 | bharatbiotech.com |
| 13 | UNICEF, Hepatitis B Vaccine Price Tender Data, 2024 | unicef.org/supply |
| 14 | US CDC, Adult Vaccination Coverage Report, 2024 | cdc.gov |
| 15 | WHO, Effective Vaccine Management Assessment, 2024 | who.int |
| 16 | US CDC, Healthy People 2030 Immunization Targets, 2024 | health.gov |
| 17 | World Bank, Global Vaccine Supply Security Brief, 2024 | worldbank.org |
| 18 | PAHO, Revolving Fund Annual Report, 2024 | paho.org |
| 19 | GlaxoSmithKline, Annual Report, 2024 | gsk.com |
| 20 | Merck & Co., Annual Report, 2024 | merck.com |
| 21 | Africa CDC, Local Vaccine Manufacturing Roadmap, 2023 | africacdc.org |
| 22 | ECDC, Hepatitis B Surveillance Report, 2024 | ecdc.europa.eu |
| 23 | WHO, Global Health Sector Strategy on Viral Hepatitis, 2024 | who.int |

### Section 14 — Frequently Asked Questions

Q1. How should procurement teams evaluate suppliers in the hepatitis B vaccine Market?

Weigh the WHO prequalification status, fill-finish capacity location, and cold-chain footprint alongside per-dose price. Suppliers with regional manufacturing increasingly win tender scoring on supply-security criteria.

Q2. What competitive dynamics favor smaller manufacturers in the hepatitis B vaccine Market?

Pooled-procurement tiers reward price competitiveness over brand, letting regional producers win Gavi-aligned volume. Specialization in pentavalent or hexavalent formats also creates defensible niches.

Q3. How does combination vaccine adoption affect buyer decisions?

Combination products cut injection visits and cold-chain trips, lowering total program cost. Buyers must verify hexavalent prequalification and confirm antigen compatibility before switching schedules.

Q4. What regulatory nuance shapes adult demand in the hepatitis B vaccine Market?

The 2022 US recommendation extending vaccination to adults 19–59 created a structural adult segment. Reimbursement coding and pharmacy-administration rules now determine real-world uptake.

Q5. What integration challenges arise with needle-free delivery platforms?

Needle-free injectors require staff retraining and device-specific maintenance protocols. Programs should pilot in controlled settings before scaling to confirm wastage and reliability gains.

Q6. Which emerging use cases could expand demand beyond routine immunization?

Self-administration via microarray patches and pharmacy-channel adult catch-up open non-clinical settings. These could materially widen the addressable base by the early 2030s.

Q7. How should investors weigh price erosion against volume growth?

Volume gains in low-income tiers rarely offset margin compression from sub-USD-0.30 tender pricing. Value capture concentrates in adult and combination segments rather than monovalent birth-dose supply.

## Market Drivers

### 医疗支出上升

各地区医疗支出的增加是乙型肝炎疫苗市场的一个显著驱动因素。随着各国在医疗基础设施和预防措施上的投资增加，疫苗接种项目的拨款可能会增加。这一趋势在发展中国家尤为明显，在这些国家，提高医疗服务的可及性是优先事项。对公共卫生倡议的资金增强可以导致疫苗接种活动的扩大，从而提高乙型肝炎疫苗的接种率。此外，随着医疗系统的发展，越来越强调预防性护理，这与乙型肝炎疫苗市场的目标相一致。医疗支出与疫苗接种率之间的相关性表明，持续对健康服务的投资将对市场产生积极影响。

### 疫苗技术的进展

疫苗开发的技术进步正在显著影响乙型肝炎疫苗市场。重组DNA技术等创新提高了疫苗的有效性和安全性。这些进展不仅改善了乙型肝炎疫苗的免疫原性，还促进了可以保护多种疾病的联合疫苗的开发。新配方和给药方法的引入，如皮内疫苗和口服疫苗，可能进一步扩大市场。随着研究的不断发展，更有效和更易获得的疫苗的潜力可能导致疫苗接种率的提高。这一技术进步可能会吸引投资和合作，从而刺激乙型肝炎疫苗市场的增长。

### 政府疫苗接种计划

政府的倡议和疫苗接种计划在塑造乙型肝炎疫苗市场中发挥着关键作用。许多国家实施了国家免疫计划，旨在根除乙型肝炎，特别是在高流行地区。这些计划通常包括为高风险人群提供免费或补贴的疫苗，这可以显著提高疫苗接种覆盖率。例如，拥有强大疫苗接种政策的国家报告了乙型肝炎流行率的显著下降。政府承诺为疫苗接种活动分配资源，不仅增强了公共健康，还推动了乙型肝炎疫苗市场的需求。随着越来越多的国家认识到疫苗接种在控制乙型肝炎中的重要性，预计市场将经历持续增长。

### 乙型肝炎发病率上升

乙型肝炎感染的上升发病率是乙型肝炎疫苗市场的一个关键驱动因素。根据健康组织的说法，目前有数百万人正生活在慢性乙型肝炎中，导致严重的肝脏并发症。这一令人担忧的趋势需要有效的疫苗接种策略来遏制病毒的传播。世界卫生组织估计，全球约有2.57亿人感染乙型肝炎，突显了疫苗接种的迫切需求。随着对该疾病流行程度的认识不断提高，医疗服务提供者和政府可能会优先考虑疫苗接种计划，从而推动乙型肝炎疫苗市场的发展。乙型肝炎感染的日益严重凸显了预防措施的重要性，这可能导致未来几年疫苗需求的激增。

### 日益增长的公众对乙型肝炎的认识

公众对乙型肝炎及其潜在健康后果的日益关注是推动乙型肝炎疫苗市场的重要因素。教育宣传活动和外展项目在告知社区有关乙型肝炎相关风险（包括肝病和癌症）方面发挥了重要作用。随着人们对该疾病的了解加深，疫苗接种的需求可能会增加。公共卫生组织正在积极推广疫苗接种作为预防措施的重要性，这可能导致更高的接种率。这种增强的意识不仅鼓励个人寻求接种，还影响医疗服务提供者更频繁地推荐乙型肝炎疫苗。因此，教育和意识的增强预计将促进乙型肝炎疫苗市场的发展。

## Future Outlook

乙型肝炎疫苗市场预计将在2024年至2035年间以4.73%的年均增长率增长，推动因素包括疫苗接种意识的提高和政府的倡议。

**New opportunities:**

- 扩大疫苗咨询的远程医疗服务

到2035年，乙型肝炎疫苗市场预计将实现强劲增长和更高的可及性。

## Segment Insights

### 按类型：单价（最大）与组合（增长最快）

在乙型肝炎疫苗市场中，市场份额的分布显示单价疫苗已成为最大的细分市场，因其针对乙型肝炎病毒的免疫接种而受到青睐。这种疫苗类型通常是初次接种的首选，特别是在乙型肝炎流行率高的地方。另一方面，组合疫苗则针对多种疾病进行一次接种，正在获得显著关注，尤其是在希望简化儿童和成人疫苗接种计划的医疗服务提供者中。

单价（主导）与组合（新兴）

单价乙型肝炎疫苗专门用于预防乙型肝炎，在市场上占据主导地位，提供简单的接种方案。它在各种全球健康倡议中被广泛接受，并建议在婴儿出生后立即接种。相比之下，组合疫苗正在迅速崛起；它们不仅提供对乙型肝炎的免疫，还包括其他疾病的抗原，从而满足更大受众的需求。它们在一次接种中提供多重保护的便利性与现代医疗趋势朝向效率和患者依从性相契合。

### 按分销渠道：医院药房（最大）与在线门户（增长最快）

在乙型肝炎疫苗市场中，医院药房占据了最大的市场份额，作为患者在门诊和住院环境中接种疫苗的主要接入点。该细分市场受益于医院提供的综合医疗服务，确保高合规性和便利性。零售药房和诊所也对市场动态产生影响，零售药房为消费者提供直接接触，而诊所则提供个性化的疫苗接种服务，增强患者参与度。

分销渠道细分市场的增长趋势受到疫苗接种意识提高和向便利驱动的医疗解决方案转变的影响。在线门户已成为增长最快的渠道，反映了消费者行为的变化，越来越多的患者倾向于在线预约和家庭送货服务的便利性。药房和诊所提供创新解决方案的适应性，例如移动疫苗接种单元，进一步推动了该细分市场的扩展，以满足市场不断变化的需求。

医院药房（主导）与在线门户（新兴）

医院药房在乙型肝炎疫苗市场中处于前沿地位，因为它们在医疗系统中建立了可靠的存在，为疫苗接种提供了一个可靠和受控的环境。它们的主导地位得到了全面护理的支持，通常与医疗专业人员合作，以确保患者遵循疫苗接种计划。另一方面，在线门户代表了一个新兴的细分市场，迎合了寻求便利的科技精明人群。在线门户的吸引力在于它们能够简化疫苗获取的过程，使患者能够远程预约并接收后续通知。这种对数字解决方案日益增长的偏好反映了消费者行为的重大转变，反映了医疗保健向数字化的更广泛趋势。

### 按年龄组：儿童（最大）与老年人（增长最快）

乙型肝炎疫苗市场主要分为三个主要年龄组：儿童组、成人组和老年组。在这些细分市场中，儿童组占据了市场的最大份额，因为疫苗接种计划通常在儿童时期被强制执行，从而促进了早期对乙型肝炎的广泛免疫。该细分市场不仅反映了早期预防策略的重要性，还受益于政府的宣传活动，这些活动促进了儿童疫苗的获取和接种。

儿科（主导）与老年科（新兴）

儿科领域在乙型肝炎疫苗市场中占据主导地位，这主要得益于强有力的免疫接种计划和优先考虑儿童疫苗覆盖的政策。卫生当局提倡接种疫苗以建立群体免疫，避免疫情爆发，从而推动需求。相反，老年人群体正成为增长最快的类别，因对乙型肝炎的认识在老年人中日益增强，尤其是那些有合并症的人。老年人群体的旅行增加以及对预防性医疗的高度关注，为该领域带来了显著的增长机会。

## Regional Market Share Analysis

### 北美：疫苗的主要市场

北美是乙型肝炎疫苗最大的市场，占全球市场份额的约40%。该地区受益于先进的医疗基础设施、高水平的意识以及强有力的政府疫苗接种计划。来自FDA等机构的监管支持进一步推动了市场增长，确保安全有效疫苗的可用性。乙型肝炎的日益普遍和医疗支出的增加也是重要的增长驱动因素。

美国是该地区的主导者，主要制药公司如默克公司和艾伯维在市场中处于领先地位。加拿大也做出了重要贡献，专注于公共卫生宣传以提高疫苗接种率。竞争格局以创新和关键参与者之间的战略合作为特征，确保稳定的疫苗供应以满足日益增长的需求。

### 欧洲：监管支持与创新

欧洲正日益重视乙型肝炎疫苗接种，推动这一趋势的是日益增强的意识和监管支持。该地区占全球市场份额的约30%，德国和法国等国走在前列。欧洲药品管理局（EMA）在确保疫苗安全性和有效性方面发挥着关键作用，这增强了公众信任并鼓励疫苗接种。国家卫生政策越来越优先考虑乙型肝炎的预防，促进了市场增长。

德国是欧洲最大的市场，其次是法国和英国。竞争格局中有关键参与者如赛诺菲和葛兰素史克，他们积极参与研究和开发，以改善疫苗配方。政府与制药公司之间的合作努力也很明显，旨在提高疫苗接种率并有效抗击该疾病。强大的医疗系统的存在进一步支持了市场的扩展。

### 亚太地区：具有高潜力的新兴市场

亚太地区在乙型肝炎疫苗市场中是一个新兴的强国，占全球市场份额的约25%。该地区的增长受到医疗投资增加、对乙型肝炎的认识提高以及政府推动疫苗接种的举措的推动。中国和印度等国处于前沿，面临重大风险人群，导致对疫苗的需求激增。监管机构也在增强其框架，以促进疫苗的批准和分发。

中国是该地区最大的市场，主要参与者如中国国家药品集团和印度血清研究所支持这一市场。印度也在快速增长，本地制造商如巴拉特生物技术和Zydus Cadila正在扩大其生产能力。竞争格局以跨国公司和本地公司混合为特征，确保为消费者提供多样化的疫苗选择。政府与私营部门之间的合作努力对于提高疫苗接种覆盖率至关重要。

### 中东和非洲：未开发的市场与挑战

中东和非洲代表了一个未开发的乙型肝炎疫苗市场，占全球市场份额的约5%。该地区面临着医疗基础设施有限和对乙型肝炎的认识水平不一等挑战。然而，政府的日益增加的举措和国际支持正在推动疫苗接种计划的需求。南非和尼日利亚等国正专注于改善医疗服务的可及性和疫苗接种率，这对市场增长至关重要。

南非是该地区的领先市场，努力增强公共卫生宣传和疫苗接种活动。关键参与者如葛兰素史克和本地制造商的存在对于满足日益增长的需求至关重要。竞争格局正在演变，政府与制药公司之间的合作旨在改善疫苗的分发和可及性。解决医疗基础设施中的挑战对于实现该市场的全部潜力至关重要。

## Competitive Benchmarking

The Hepatitis B Vaccine Market is characterized by a dynamic competitive landscape, driven by increasing global awareness of hepatitis B and the need for effective vaccination strategies. Key players such as GSK (GB), Merck & Co. (US), and Sanofi (FR) are at the forefront, each adopting distinct strategies to enhance their market presence. GSK (GB) focuses on innovation and research, particularly in developing next-generation vaccines, while Merck & Co. (US) emphasizes strategic partnerships to expand its distribution networks. Sanofi (FR) is actively pursuing regional expansion, particularly in emerging markets, which appears to be a critical component of its growth strategy. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and market penetration.
In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. The market is moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and strategies, but it also means that companies must continuously innovate to maintain their competitive edge. The influence of key players is significant, as their actions can set trends that smaller companies may follow.
In August 2025, Merck & Co. (US) announced a collaboration with a leading biotechnology firm to develop a novel adjuvant for its hepatitis B vaccine. This strategic move is likely to enhance the vaccine's efficacy and could position Merck as a leader in the market, particularly as the demand for more effective vaccines continues to rise. The collaboration underscores the importance of innovation in maintaining competitive advantage in this sector.
In September 2025, Sanofi (FR) launched a new initiative aimed at increasing vaccine accessibility in low-income regions. This initiative includes partnerships with local governments and NGOs to facilitate distribution. By addressing accessibility, Sanofi not only enhances its corporate social responsibility profile but also expands its market reach, potentially leading to increased sales in underserved areas. This approach reflects a growing trend among pharmaceutical companies to align business strategies with social impact.
In July 2025, Bharat Biotech (IN) received regulatory approval for a new hepatitis B vaccine formulation that promises to be more effective and easier to administer. This development is significant as it positions Bharat Biotech to compete more aggressively in both domestic and international markets. The approval may also encourage further investment in research and development, as the company seeks to capitalize on this momentum.
As of October 2025, the market is witnessing trends such as digitalization and sustainability, which are reshaping competitive dynamics. Companies are increasingly leveraging technology to enhance vaccine distribution and monitoring processes. Strategic alliances are becoming more prevalent, as firms recognize the value of collaboration in navigating complex market challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and reliable supply chains, which will be essential for sustaining market leadership.

## Recent News & Developments

乙型肝炎病毒感染的日益普遍、对该疾病及疫苗的认识不断提高，以及新型更有效疫苗的推出是推动该市场增长的主要因素。

市场的最新新闻动态包括美国食品药品监督管理局（FDA）批准了一种新疫苗，并启动了一种新疫苗候选者的临床试验。这些进展表明乙型肝炎疫苗市场的未来前景光明。

## Report Scope

| 2024年市场规模 | 2.022（十亿美元） |
| --- | --- |
| 2025年市场规模 | 2.118（十亿美元） |
| 2035年市场规模 | 3.362（十亿美元） |
| 复合年增长率（CAGR） | 4.73%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 疫苗输送系统中的新兴技术提高了乙型肝炎疫苗市场的可及性。 |
| 主要市场动态 | 对乙型肝炎疫苗的需求上升推动了制药制造商和医疗服务提供者之间的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 截至2024年，乙型肝炎疫苗市场的当前估值是多少？**
A: 2024年，乙型肝炎疫苗市场的价值为20.22亿美元。

**Q: 2035年乙型肝炎疫苗市场的预计市场估值是多少？**
A: 预计到2035年，市场将达到33.62亿美元。

**Q: 在2025年至2035年的预测期内，乙型肝炎疫苗市场的预期CAGR是多少？**
A: 2025年至2035年期间，乙型肝炎疫苗市场的预期CAGR为4.73%。

**Q: 在乙型肝炎疫苗市场中，哪些公司被视为关键参与者？**
A: 市场的主要参与者包括GSK、默克公司、赛诺菲、艾伯维、巴拉特生物技术、印度血清研究所、中国国家药品集团和Zydus Cadila。

**Q: 单价疫苗和组合疫苗的市场细分在估值方面如何比较？**
A: 在2024年，单价段的价值为12.12亿美元，而组合段的价值为8.1亿美元。

**Q: 在乙型肝炎疫苗市场中，儿童、成人和老年人年龄组的预计估值是多少？**
A: 儿科细分市场预计将从6.06亿美元增长到9.78亿美元，成人细分市场将从6.06亿美元增长到10.78亿美元，老年细分市场将从8.1亿美元增长到13.06亿美元。

**Q: 在乙型肝炎疫苗市场中，使用了哪些分销渠道，它们的估值是多少？**
A: 分销渠道包括医院药房，价值6.06亿美元；零售药房，价值4.04亿美元；诊所，价值6.06亿美元；以及在线门户，价值4.06亿美元，预计在2024年。

**Q: 到2035年，组合疫苗领域的预期增长轨迹是什么？**
A: 组合疫苗细分市场预计将从2024年的8.1亿美元增长到2035年的13.84亿美元。

**Q: 2024年医院药房的市场表现与在线门户相比如何？**
A: 在2024年，医院药房的估值为6.06亿美元，而在线门户的估值为4.06亿美元。

**Q: 乙型肝炎疫苗市场的增长预测对未来投资有什么影响？**
A: 预计到2035年增长到33.62亿美元，这表明在疫苗开发和分发方面存在潜在的投资机会。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hepatitis-b-vaccine-market-29415*